BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9563879)

  • 1. Philadelphia chromosome-positive myeloid cells in the peripheral blood of chronic myelogenous leukemia patients: comparison with the frequency detected in cycling cells of the bone marrow.
    Seong D; Thall P; Kantarjian HM; Talpaz M; Swantkowski J; Xu J; Shen Y; Glassman A; Ramagli L; Siciliano MJ
    Clin Cancer Res; 1998 Apr; 4(4):861-7. PubMed ID: 9563879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of detection of minimal residual disease by 'hypermetaphase' fluorescent in situ hybridization after allogeneic BMT for chronic myelogenous leukemia.
    Seong D; Giralt S; Fischer H; Hayes K; Glassman A; Arlinghaus R; Xu J; Kantarjian H; Siciliano M; Champlin R
    Bone Marrow Transplant; 1997 Mar; 19(6):565-70. PubMed ID: 9085736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic role of conventional cytogenetics and fluorescence in situ hybridization (FISH) in chronic myeloid leukemia patients.
    Jha CB; Kucheria K; Choudhary VP
    Kathmandu Univ Med J (KUMJ); 2006; 4(2):171-5. PubMed ID: 18603893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interphase FISH for follow-up of Philadelphia chromosome-positive chronic myeloid leukemia treatment.
    Douet-Guilbert N; Morel F; Le Charpentier T; Le Bris MJ; Herry A; Morice P; Bourquard P; Abgrall JF; Berthou C; De Braekeleer M
    Anticancer Res; 2004; 24(4):2535-9. PubMed ID: 15330210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.
    Schoch C; Schnittger S; Bursch S; Gerstner D; Hochhaus A; Berger U; Hehlmann R; Hiddemann W; Haferlach T
    Leukemia; 2002 Jan; 16(1):53-9. PubMed ID: 11840263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate.
    Fugazza G; Miglino M; Bruzzone R; Quintino S; Gatti AM; Grasso R; Gobbi M; Frassoni F; Sessarego M
    J Exp Clin Cancer Res; 2004 Jun; 23(2):295-9. PubMed ID: 15354415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
    Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
    Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells.
    Yanagi M; Shinjo K; Takeshita A; Tobita T; Yano K; Kobayashi M; Terasaki H; Naoe T; Ohnishi K; Ohno R
    Leukemia; 1999 Apr; 13(4):542-52. PubMed ID: 10214860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow derived mesenchymal stem cells from chronic myeloid leukemia t(9;22) patients are devoid of Philadelphia chromosome and support cord blood stem cell expansion.
    Jootar S; Pornprasertsud N; Petvises S; Rerkamnuaychoke B; Disthabanchong S; Pakakasama S; Ungkanont A; Hongeng S
    Leuk Res; 2006 Dec; 30(12):1493-8. PubMed ID: 16839603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The application of fluorescence in situ hybridization in detecting chronic myeloid leukemia].
    Qiu HR; Miao KR; Wang R; Qiao C; Zhang JF; Zhang SJ; Qian SX; Xu W; Li JY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Apr; 26(2):207-10. PubMed ID: 19350518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia.
    Lundán T; Juvonen V; Mueller MC; Mustjoki S; Lakkala T; Kairisto V; Hochhaus A; Knuutila S; Porkka K
    Haematologica; 2008 Feb; 93(2):178-85. PubMed ID: 18223279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early detection of relapse by hypermetaphase fluorescence in situ hybridization after allogeneic bone marrow transplantation for chronic myeloid leukemia.
    Seong CM; Giralt S; Kantarjian H; Xu J; Swantkowski J; Hayes K; Glassman AB; Khouri I; Korbling M; Thall P; Siciliano MJ; Champlin RE
    J Clin Oncol; 2000 May; 18(9):1831-6. PubMed ID: 10784623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High reliability and sensitivity of the BCR/ABL1 D-FISH test for the detection of BCR/ABL rearrangements.
    Pelz AF; Kröning H; Franke A; Wieacker P; Stumm M
    Ann Hematol; 2002 Mar; 81(3):147-53. PubMed ID: 11904740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study of deletion of derivative chromosome 9 in patients with Ph+ chronic myeloid leukemia].
    Wu W; Xue YQ; Wu YF; Pan JL; Shen J
    Zhonghua Xue Ye Xue Za Zhi; 2006 Mar; 27(3):183-6. PubMed ID: 16792921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Application of interphase fluorescence in situ hybridization for determination of the tumor load in chronic myeloid leukemia].
    Du QF; Zhou SY; Liu XL; Song LL; Zhang Y
    Ai Zheng; 2003 Jun; 22(6):612-5. PubMed ID: 12948411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A two-color BCR-ABL probe that greatly reduces the false positive and false negative rates for fluorescence in situ hybridization in chronic myeloid leukemia.
    Grand FH; Chase A; Iqbal S; Nguyen DX; Lewis JL; Marley SB; Davidson RJ; Goldman JM; Gordon MY
    Genes Chromosomes Cancer; 1998 Oct; 23(2):109-15. PubMed ID: 9739013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of trisomy 8 in philadelphia chromosome-positive CML patients using conventional cytogenetic and interphase fluorescence in situ hybridization techniques and its relation to c-myc involvement.
    Oudat R; Khan Z; Glassman AB
    Ann Clin Lab Sci; 2001 Jan; 31(1):68-74. PubMed ID: 11314864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Autogeneic peripheral blood hemopoietic stem cell transplantation for chronic myeloid leukemia with imatinib mesylate-induced negative Philadelphia chromosome].
    Meng FY; Sun J; Liu QF; Xu D; Yang LJ; Song LL; Liu XL; Xu B; Zhou SY
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Dec; 23(12):1301-2, 1306. PubMed ID: 14678896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coexistence of Philadelphia chromosome positive cells with and without der(9) deletion in a patient with chronic myelogenous leukemia.
    Xinh PT; Vu HA; Nghia H; Binh NT; Van Be T; Van Binh T; Tokunaga K; Sato Y
    Cancer Genet Cytogenet; 2006 Jan; 164(2):122-7. PubMed ID: 16434314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment.
    Seong DC; Kantarjian HM; Ro JY; Talpaz M; Xu J; Robinson JR; Deisseroth AB; Champlin RE; Siciliano MJ
    Blood; 1995 Sep; 86(6):2343-9. PubMed ID: 7662980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.